Teva Pharmaceutical Industries Ltd.’s acquisition of Allergan PLC’s generic drug business for $40.5 billion will secure its position as the top Rx generic drug company and boost its OTC private label play.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?